

Applicant : Davis et al.  
Serial No. : 09/761,569  
Filed : January 16, 2001  
Page : 4

Attorney's Docket No.: 10363-003004 / UMMC Ref.:  
95-10

### REMARKS

Applicants are submitting this Preliminary Amendment concurrently with a Response to Restriction Requirement. Elected claims 51 and 52 are amended to clarify their language. New claims 56-74 are added. Support for new claims 56-74 is provided throughout the application, e.g., support for claim 56 is found at page 10, line 7; support for claims 57 and 58 is at page 10, lines 16-24; support claim 59 is at page 10, lines 20-23; support for claim 60 is at page 11, lines 4-5; support for claim 61 is at page 46, lines 11-13; support for claim 62 is at page 10, lines 23-25 and page 48, lines 2-3; support for claims 63 and 64 is at page 47, lines 8-11; support for claims 65 and 66 is at page 10, line 26-page 11, lines 2-3; support for claim 67 is at page 11, lines 2-3; support for claim 68 is at page 10, lines 30-31 and page 47, lines 22-29; support for claims 69-73 is found at page 10, line 26-page 11, line 11; and support for claim 74 is at page 10, lines 31-32. No new matter is added by the amendment.

### CONCLUSION

Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks that all claims be examined. Please apply any charges or credits to Deposit Account No. 06-1050 referencing attorney docket no. 10363-003004.

Respectfully submitted,

Date: June 19, 2002

J. Peter Fasse  
J. Peter Fasse  
Reg. No. 32,983

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

Applicant : Davis et al.  
Serial No. : 09/761,569  
Filed : January 16, 2001  
Page : 5

Attorney's Docket No.: 10363-003004 / UMMC Ref.:  
95-10

**Version with markings to show changes made**

In the claims:

Claims 51 and 52 have been amended as follows:

51. (Amended once) A method of treating an MKK-mediated disorder in a patient, the method comprising administering to the patient a therapeutically effective amount of a reagent that modulates MKK activity.

52. (Amended once) The method of claim 51, wherein the [said] MKK-mediated disorder is selected from the group consisting of ischemic heart disease, kidney failure, oxidative liver damage, respiratory distress syndrome, burns from heat, [and] radiation burns, septic shock, rheumatoid arthritis, autoimmune disorders, and inflammatory diseases.

Claims 1, 32 to 44, and 50 have been canceled.

New claims 56 to 74 have been added.

RECEIVED  
JUL 08 2002  
TECH CENTER 1600/2900